Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in
combination with cemiplimab in patients with metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
American Association for Cancer Research Genzyme, a Sanofi Company